Ratings Cytokinetics, Incorporated

Equities

CYTK

US23282W6057

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-23 pm EDT			5-day change	1st Jan Change
48.98 ^USD	-17.31%		-18.26%	-41.33%

May. 23	Raymond James Adjusts Price Target on Cytokinetics to $70 From $92, Maintains Outperform Rating	MT
May. 23	Sector Update: Health Care Stocks Flat to Lower Premarket Thursday	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
One of the major weak points of the company is its financial situation.
The company's "enterprise value to sales" ratio is among the highest in the world.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
CYTOKINETICS, INCORPORATED	-41.33%	5.62B	B
VERTEX PHARMACEUTICALS INCORPORATED	+10.79%	116B	B+
REGENERON PHARMACEUTICALS, INC.	+11.65%	106B	B+
BIONTECH SE	-6.20%	23.89B	B+
ARGENX SE	-3.20%	21.58B	B
GENMAB A/S	-11.14%	18.96B	A-
BEIGENE, LTD.	-13.41%	16.33B	B
WUXI APPTEC CO., LTD.	-40.50%	16.96B	A-
NEUROCRINE BIOSCIENCES, INC.	+6.64%	14.14B	C+
SAREPTA THERAPEUTICS, INC.	+31.84%	12.02B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes